RevMed's Pancreatic Cancer Drug Approved at High Price
Revolution Medicines received US approval for Rasonque, a groundbreaking daily pill that extends survival in advanced pancreatic cancer patients by targeting the RAS protein mutation common in the disease. Priced at over $475,000 annually, it represents one of the most expensive cancer treatments ever developed and marks a significant therapeutic advance against this difficult-to-treat cancer type.
1 Article
Trace's outlet lean is shown first — tap Left / Center / Right on each source to add your rating too.
- BloombergTrace: Center
RevMed’s Pancreatic Cancer Pill Priced Above $475K per Year
Revolution Medicines received US approval for Rasonque, a groundbreaking daily pill that extends survival in advanced pancreatic cancer patients by targeting the RAS protein mutation common in the disease. Priced at over $475,000 annually, it represents one of the most expensive cancer treatments ever developed and marks a significant therapeutic advance against this difficult-to-treat cancer type.
Rate outletRead original